Nature Communications

Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial

2026-05-07

Full text

DOI https://doi.org/10.1038/s41467-026-72984-7